2. Search Result
Search Result
Results for "

Cas Inhibitors

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

1

Screening Libraries

Targets Recommended:
Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-107845
    SCR7 pyrazine
    Maximum Cited Publications
    20 Publications Verification

    		 DNA/RNA Synthesis Apoptosis Cancer
    SCR7 pyrazine is a DNA ligase IV inhibitor that blocks nonhomologous end-joining (NHEJ) in a ligase IV-dependent manner. SCR7 pyrazine increases the efficiency of Cas9-mediated homology-directed repair (HDR). SCR7 pyrazine induces cell apoptosis and has anticancer activity .
    SCR7 pyrazine
  • HY-150279
    PolQi2
    3 Publications Verification

    		 DNA/RNA Synthesis Others
    PolQi2 is a PolΘ inhibitor that targets and inhibits alt-EJ (alternative end-joining) repair by inhibiting the helicase domain at the N-terminus of PolΘ. PolQi2 enhances the precision and integration efficiency of gene editing at different loci and in various cell lines. Furthermore, the combined use of PolQi2 with DNA-PK inhibitors reduces the off-target effects of Cas9. PolQi2 can be used in gene editing research .
    PolQi2
  • HY-159078
    PolQi1

    		DNA/RNA Synthesis Cancer
    PolQi1 is a selective inhibitor targeting the Polθ domain of DNA polymerase. PolQi1 inhibits the Polθ-mediated microhomology end joining (TMEJ/alt-EJ) pathway, reducing insertion/deletion (Indels) and imprecise editing events during DNA repair. PolQi1 can enhance the efficiency and accuracy of homology-directed repair (HDR) or Prime editing, and reduce off-target effects; and in combination with DNA-PK inhibitor AZD-7648 (HY-111783), exert efficient genome editing capabilities with dual pathway regulation. PolQi1 can be mainly used in gene editing research (such as CRISPR-Cas9 or Prime editing system optimization) to improve the precision editing efficiency of difficult-to-edit cells (such as primary hepatocytes and mouse embryos) .
    PolQi1
  • HY-148730
    BRD7586
    1 Publications Verification

    		 Bacterial Cancer
    BRD7586 is a potent and selective Streptococcus pyogenes Cas9 (SpCas9) inhibitor. BRD7586 specifically engages SpCas9 but not Cas12a in cells and enhances SpCas9 specificity at multiple loci. BRD7586 inhibits SpCas9 at multiple genomic loci irrespective of the mode of SpCas9 delivery .
    BRD7586
  • HY-136251
    BRD0539

    		Bacterial Infection
    BRD0539 is a Streptococcus pyogenes Cas9 (SpCas9) inhibitor with an IC50 of 22 μM in an in vitro DNA cleavage assay .
    BRD0539
  • HY-118467
    Benzolamide
    2 Publications Verification

    CL11366

    		 Carbonic Anhydrase Neurological Disease Cancer
    Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the research of glaucoma and seizures .
    Benzolamide
  • HY-128153
    Thienopyridone
    1 Publications Verification

    		 Phosphatase Apoptosis Cancer
    Thienopyridone is a potent and selective phosphatase of regenerating liver (PRL) phosphatase inhibitor with IC50s of 173 nM, 277 nM and 128 nM for PRL-1, PRL-2, and PRL-3, respectively. Thienopyridone shows minimal effects on other phosphatases. Thienopyridone induces p130Cas cleavage and apoptosis and has anticancer effects .
    Thienopyridone
  • HY-144118
    Cas9-IN-1

    		Bacterial Others
    Cas9-IN-1 is a potent Cas9 inhibitor (IC50=7.02 μM), acting by binding to apo-Cas9 to prevent Cas9:gRNA complex formation .
    Cas9-IN-1
  • HY-158304
    Rac1-IN-4

    		Ras Cancer
    Rac1-IN-4 (Cas: 2924486-45-1) is a Rac1 inhibitor .
    Rac1-IN-4
  • HY-122650
    PHY34

    		Autophagy Cancer
    PHY34 is an inhibitor that inhibits ATP6V0A2 and CAS thereby inhibiting autophagy, and has a nanomolar effect. PHY34 inhibits cancer cell growth by inducing apoptosis and inhibits tumor growth in xenograft models. PHY34 can be used for research on high grade serous ovarian cancer .
    PHY34
  • HY-144119
    Cas9-IN-2

    		Bacterial Others
    Cas9-IN-2 is a potent Cas9 inhibitor (IC50=246 μM), Cas9-IN-2 acts by binding to apo-Cas9 to prevent Cas9:gRNA complex formation, which can potentially be applied to modulate and control Cas9 activity in various applications .
    Cas9-IN-2
  • HY-145692
    Cas9-IN-3

    		Bacterial Others
    Cas9-IN-3 is a potent Cas9 inhibitor (IC50=28 μM) .
    Cas9-IN-3
  • HY-131528
    Tenilsetam

    Cas 997

    		 TNF Receptor Neurological Disease Metabolic Disease
    Tenilsetam (CAS 997) is an antidementia compound. Tenilsetam is an advanced glycation end product (AGE) inhibitor. Tenilsetam inhibits early retinopathy in experimental diabetes rats .
    Tenilsetam
  • HY-147956
    hCA VB-IN-1

    		Carbonic Anhydrase Neurological Disease Metabolic Disease
    hCA VB-IN-1 (compound 15) is a potent and selective hCA VB (carbonic anhydrase) inhibitor, with a KI of 515.7 nM .
    hCA VB-IN-1
  • HY-162671
    BuChE-IN-12

    		Cholinesterase (ChE) Neurological Disease
    BuChE-IN-12 is a selective BuChE inhibitor (IC50=0.52 µM) that acts via affecting CAS and PAS sites and has potential effects against oxidative stress. BuChE-IN-12 can be used in the study of Alzheimer's disease .
    BuChE-IN-12
  • HY-118467R
    Benzolamide (Standard)

    CL11366 (Standard)

    		 Carbonic Anhydrase Reference Standards Neurological Disease Cancer
    Benzolamide (Standard) is the analytical standard of Benzolamide. This product is intended for research and analytical applications. Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the research of glaucoma and seizures .
    Benzolamide (Standard)
  • HY-150728
    AChE-IN-22

    		Cholinesterase (ChE) Neurological Disease
    AChE-IN-22 (compound 10q) is a selective acetylcholinesterase (AChE) inhibitor against AChE and BuChE with the IC50 values of 0.88 μM and 10 μM, respectively. AChE-IN-22 can bind to both the CAS (catalytic active site) and PAS (peripheral anionic site) of AChE and has the potential for the research of Alzheimer's disease .
    AChE-IN-22
  • HY-149484
    AChE/BChE-IN-15

    		Cholinesterase (ChE) Neurological Disease
    AChE/BChE-IN-15 (Compound 6d) is an AChE/BChE inhibitor, with IC50s of 20 nM and 220 nM respectively. AChE/BChE-IN-15 binds to both catalytic anionic site (CAS) and peripheral anionic site (PAS) in the active sites of AChE and BChE. AChE/BChE-IN-15 can be used for research of Alzheimer’s disease .
    AChE/BChE-IN-15
  • HY-175315
    Carbonic anhydrase-IN-34

    		Carbonic Anhydrase Neurological Disease Metabolic Disease Cancer
    Carbonic anhydrase-IN-34 is a carbonic anhydrases (CAs) inhibitor (compound 9d) with IC50s of 1.01 μM against hCA-II, 0.21 μM against hCA-IX and 0.88 μM against hCA-XII. Carbonic anhydrase-IN-34 has potential applications in the research of several disorders, including epilepsy, glaucoma, obesity, and cancer .
    Carbonic anhydrase-IN-34
  • HY-157527
    hAChE-IN-7

    		Cholinesterase (ChE) Beta-secretase Neurological Disease
    hAChE-IN-7 (compound 5s) is a mixed inhibitor affecting both the catalytic active site (CAS) and peripheral anionic site (PAS) of hAChE. hAChE-IN-7 displays the balanced inhibitory effect on hAChE (IC50=69.8 nM) and hBuChE (IC50=68.0 nM), and exhibits inhibitory activity against β-secretase-1 (BACE-1) (IC50=3.6 μM). hAChE-IN-7 has the potential for Alzheimer's disease (AD) research .
    hAChE-IN-7
  • HY-115973
    AChE-IN-11

    		Cholinesterase (ChE) Neurological Disease
    AChE-IN-11 (compound 5C) is a triple inhibitor targeting AChE/MAO-B/BACE1 (IC50=7.9 μM, 9.9 μM, 8.3 μM, respectively) and a selective metal ion chelators. AChE-IN-11 exhibits mixed AChE inhibitory effects, binding to both CAS and PAS of AChE. AChE-IN-11 also exhibits good antioxidant activity (ORAC=2.5 eq) and potential neuroprotective effects in Alzheimer's disease .
    AChE-IN-11
  • HY-184244
    CAS-010

    Cas-13312-010

    		 Deubiquitinase Cancer
    CAS-010 (CAS-13312-010) is a potent and selective USP28 inhibitor with an IC50 of 2.2 nM against full-length USP28. CAS-010 acts as a ubiquitin-competitive inhibitor and shows higher selectivity over USP25 (IC50 = 51 nM) and other USP family members, disrupting the 53BP1-USP28 interaction and suppressing p53-dependent transcription of CDKN1A (p21), MDM2, and BAX. CAS-010 can be used for studying USP28-mediated DNA damage response and p53 signaling in cancer-related research .
    CAS-010
  • HY-107845R
    SCR7 pyrazine (Standard)

    		Reference Standards DNA/RNA Synthesis Apoptosis Cancer
    SCR7 pyrazine (Standard) is the analytical standard of SCR7 pyrazine (HY-107845). This product is intended for research and analytical applications. SCR7 pyrazine is a DNA ligase IV inhibitor that blocks nonhomologous end-joining (NHEJ) in a ligase IV-dependent manner. SCR7 pyrazine increases the efficiency of Cas9-mediated homology-directed repair (HDR). SCR7 pyrazine induces cell apoptosis and has anticancer activity .
    SCR7 pyrazine (Standard)
  • HY-181851
    AChE-IN-109

    		Cholinesterase (ChE) Neurological Disease
    AChE-IN-109 is a potent mixed-type cholinesterase inhibitor with significantly stronger inhibitory activity against AChE than BChE. AChE-IN-109 has IC50 values of 0.55 μM and 12.45 μM against AChE and BChE, respectively. AChE-IN-109 inhibits cholinesterases through a mixed-type mechanism, binds to both the catalytic active site (CAS) and peripheral anionic site (PAS) of AChE. AChE-IN-109 can be used for the study of Alzheimer’s disease (AD) .
    AChE-IN-109

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: